MASS-C Study: CDC Multistate Assessment of SARS-CoV-2 Seroprevalence (Commercial Labs)
Award Notice Posted
- Solicitation number
- 75D30122C13322
- Agency
-
CDC Office of Acquisition Services
Centers for Disease Control and Prevention, Department of Health and Human Services
- Awarded
- to Laboratory Corporation Of America
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75D30122C13322 Federal contract award
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Place of performance
- United States
Notice details come from SAM.gov. Updated .
About this opportunity
This fixed-price contract was awarded by the Centers for Disease Control and Prevention to Laboratory Corporation of America to conduct SARS-CoV-2 seroprevalence surveys in 11 states. Under the base 11-month contract valued at $10,337,800 with $4,638,600 funded initially, the contractor will identify blood specimens from commercial labs to test for COVID-19 antibodies, provide aggregate data reports every 8 weeks, and a final report. The purpose is to estimate infection and vaccination rates nationally and locally over time to inform the COVID-19 response.
Notice text
This fixed-price contract action was awarded on a full-and-open, competitive basis to Laboratory Corporation of America as a result of its propoals submitted in response to solicitation 75D301-22-R-72117.
Performance Start Date: 3/07/2022
Performance Period: Base 11-month period, and one (1) 12-month option period
Awarded Jurisdictions: AZ, D.C., DE, HI, MD, MT, NC, ND, SC, SD, and VA
Total Contract Value: $10,337,800.00
Total Funded Amount: $4,638,600.00
Place of Contract Performance: Contractor Location
The primary purpose of the multistate assessment of SARS-CoV-2 Seroprevalence in Commercial Laboratory Survey (MASS-C) is to estimate the proportion of people that have been infected by or vaccinated for SARS-CoV-2 during the ongoing epidemic over time, nationally, and by geographic location and demographic/pediatric subcategory. For the eleven (11) jurisdictions awarded by the contract, the Contractor will identify excess, remnant, or residual blood specimens from remaining volumes of previously obtained blood specimens for non-COVID-19 diagnostic or antibody testing. More specifically, the Contractor will collect and test mass amounts of specimens for CLIA-approved and/or EUA-approved ELISA, COVID-19 IgG and/or IgM serological assays, as well as reflexive microneutralization testing for specimens that are seropositive by qualitative anti-nucleocapsid assay. The Contractor will then provide CDC with data reports of aggregate findings after every 8-week collection/testing period, in addition to a final report at the end of the award performance period.
Awarded contract 75D30122C13322 to LABORATORY CORPORATION OF AMERICA HOLDINGS for 10337800.00 on 2022-03-04.
Notice history
| Notice | Type | Posted |
|---|---|---|
| MASS-C Study: CDC Multistate Assessment of SARS-CoV-2 Seroprevalence (Commercial Labs) | Award Notice | |
| This notice | Award Notice | |
| MASS-C Study: CDC Multistate Assessment of SARS-CoV-2 Seroprevalence (Commercial Labs) | Solicitation | |
| CDC Multistate Assessment of SARS-CoV-2 Seroprevalence (MASS) Study | Pre-Solicitation |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity